Researchers using synthetic bacteria to cure disease

For story suggestions or custom animation requests, contact [email protected] Visit http://archive.nextanimationstudio.com to view News Direct's complete archive of 3D news animations.

RESTRICTIONS: Broadcast: NO USE JAPAN, NO USE TAIWAN Digital: NO USE JAPAN, NO USE TAIWAN
Researchers have reached an important milestone in synthetic biology by carrying out successful trials on a group of volunteers in order to help treat people who suffer from phenylketonuria.
The genetically engineered probiotic developed by Synlogic could become the first synthetic biology-based medical treatment to be approved by the Food and Drug Administration, according the New York Times.
People who suffer from phenylketonuria, or PKU, must avoid dietary protein in foods like meat and cheese, because their bodies cannot break down the amino acid phenylalanine, or Phe.
The study, published on August 13 in Nature Biotechnology, showed that the probiotic can significantly lower Phe levels in both mouse models of PKU and in healthy monkeys, according to The Scientist.

The treatment is called SYNB1618 and is a modified version of the probiotic Escherichia coli Nissle.
Researchers say treatment with SYNB1618 is a two-step process. The first step is to get patients' blood Phe under control. The second step is to relax the diet and slowly add natural protein into their diet.

RUNDOWN SHOWS:
1. People with PKU must avoid protein because their bodies cannot breakdown Phe
2. Human trials testing the genetically engineered probiotic
3. SYNB1618 is a modified version of the probiotic Escherichia coli Nissle
4. SYNB1618 is a two-step process

VOICEOVER (in English):
"People who suffer from phenylketonuria, or PKU, must avoid dietary protein in foods like meat and cheese, because their bodies cannot break down the amino acid phenylalanine, or Phe."
"According to the New York Times, researchers at Synlogic have now carried out successful human trials using a genetically engineered probiotic in order to help treat people with PKU."
"The treatment is called SYNB1618 and is a modified version of the probiotic Escherichia coli Nissle."
"Researchers say treatment with SYNB1618 is a two-step process. The first step is to get patients' blood Phe under control. The second step is to relax the diet and slowly add natural protein into their diet."

SOURCES: New York Times, The Scientist
https://www.nytimes.com/2018/09/04/health/synthetic-biology-pku.html
https://www.the-scientist.com/news-opinion/synthetic-bacteria-help-treat-phenylketonuria-in-mice-64656